Table 3 Hazard ratio (HR) estimates of adverse events among patients treated with zotarolimus-eluting stents (ZES) or sirolimus-eluting stents (SES) in western denmark, August 2005 to October 2007

Patient level analysis

Death

0-823

135

6.3

159

3.3

1.35 (1.05-1.73)

0.018

0-30

57

31.0

50

16.0

1.66 (1.10-2.50)

0.016

31-365

62

4.1

70

2.4

1.19 (0.82-1.73)

0.388

366-823

16

3.5

39

2.5

1.26 (0.67-2.34)

0.475

Cardiac death

0-823

57

2.7

59

1.2

1.33 (0.89-2.00)

0.183

0-30

32

17.4

29

9.3

1.39 (0.80-2.41)

0.229

31-365

21

1.4

23

0.8

1.17 (0.59-2.32)

0.711

366-823

4

0.9

7

0.4

1.36 (0.31-5.95)

0.687

Noncardiac death

0-823

53

2.5

66

1.4

1.27 (0.87-1.87)

0.217

0-30

16

8.7

20

6.4

1.32 (0.65-2.66)

0.467

31-365

31

2.1

34

2.1

1.25 (0.75-2.09)

0.397

366-823

6

1.3

12

0.8

1.39 (0.50-3.89)

0.532

Myocardial infarction

31-823

66

3.5

108

2.5

0.98 (0.69-1.42)

0.964

366-823

9

2.1

30

2.0

0.99 (0.43-2.28)

0.992

Target lesion revascularization

0-823

110

5.3

91

1.9

2.16 (1.36-3.42)

0.001

Stent thrombosis

0-823

26

1.2

24

0.5

2.01 (0.76-5.34)

0.159

0-30

21

11.5

13

4.2

3.62 (0.92-14.2)

0.065

31-365

4

0.3

5

0.2

1.17 (0.18-7.39)

0.870

366-823

1

0.2

6

0.4

Not calculable

-

Lesion level analysis

Target lesion revascularization

0-823

115

4.0

96

1.5

2.48 (1.87-3.27)

<0.0001

Stent thrombosis

0-823

28

1.0

24

0.4

2.21 (1.26-3.87)

0.006

0-30

23

9.3

13

3.1

2.75 (1.38-5.47)

0.004

31-365

4

0.2

5

0.1

1.47 (0.39-5.57)

0.568

366-823

1

0.2

6

0.3

1.22 (0.14-10.9)

0.857